Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis

Redox Report

Volumn 19, Issue 1, 2014, Pages 1-7

  Toyokuni, Shinya ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Asbestos; CDKN2A 2B; Iron chelation; Iron overload; Malignant mesothelioma; Phlebotomy

Indexed keywords

AMOSITE; ASBESTOS; ASBESTOS FIBER; CHRYSOTILE; CROCIDOLITE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEFERASIROX; DEFEROPRINE; IRON; IRON CHELATING AGENT; IRON SACCHARATE; NITRILOTRIACETATE IRON; NITRILOTRIACETIC ACID; PODOPLANIN; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER LOCALIZATION; CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENE DELETION; HUMAN; INCUBATION TIME; IRON OVERLOAD; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; NONHUMAN; PHLEBOTOMY; PLEURA MESOTHELIOMA; POINT MUTATION; PRIORITY JOURNAL; RARE DISEASE; REVIEW; RISK FACTOR; SEX DIFFERENCE;

ASBESTOS; CDKN2A/2B; IRON CHELATION; IRON OVERLOAD; MALIGNANT MESOTHELIOMA; PHLEBOTOMY;

ADSORPTION; ANIMALS; ASBESTOS; ASBESTOSIS; BENZOATES; CARCINOGENS, ENVIRONMENTAL; CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; COMPARATIVE GENOMIC HYBRIDIZATION; FERRIC COMPOUNDS; GENES, P16; GLUCARIC ACID; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; JAPAN; KIDNEY NEOPLASMS; MALE; MESOTHELIOMA; MINERAL FIBERS; PERITONEAL NEOPLASMS; PHLEBOTOMY; PLEURAL NEOPLASMS; RATS; TRIAZOLES;

EID: 84891872211     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000213y.0000000075     Document Type: Review

References (61)

1. Roggli VL, Oury TD, Sporn TA, editors. Pathology of asbestos-associated diseases. 2nd ed. New York: Springer Verlag; 2004.
2. IARC, WHO. Asbestos (chrysotile, amosite, crocidolite, tremo-lite, actinolite, and anthophyllite). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans A Review of Human Carcinogens; Part C: Arsenic, Metals, Fibres, and Dusts. 100C Lyon, France; 2012. p. 219-309.
3. Pass HI, Vogelzang NJ, Carbone M, editors. Malignant mesothelioma: advances in pathogenesis, diagnosis, and transla-tional therapies. New York, NY: Springer Science + Business Media Inc.; 2005.
4. Toyokuni S. Mechanisms of asbestos-induced carcinogenesis. Nagoya J Med Sci 2009;71(1-2):1-10.
5. Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health 2013;34: 205-16.
6. Churg A, Cagle PT, Roggli VL. Tumors of the serosal membranes. Silver Spring, Maryland: ARP Press; 2006.
7. Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133(8):1317-31.
8. Bianchi C, Bianchi T. Malignant mesothelioma in Eastern Asia. Asian Pacific J Cancer Prev 2012;13(10):4849-53
9. Heelan R. Staging and response to therapy of malignant pleural mesothelioma. Lung Cancer 2004;45(Suppl 1):s59-s61.
10. Nagai H, Chew S, Okazaki Y, Funahashi S, Namba T, Kato T, et al. Metamorphosis of mesothelial cells wtih active horizontal motility in tissue culture. Sci Rep 2013;3:1144.
11. Yamashita K, Nagai H, Kondo Y, Misawa N, Toyokuni S. Evaluation of two distinct methods to quantify the uptake of crocidolite fibers by mesothelial cells. J Clin Biochem Nutr 2013; 53(1):27-35.
12. Jiang L, Nagai H, Ohara H, Hara S, Tachibana M, Hirano S, et al. Characteristics and modifying factors of asbestos-induced oxidative DNA damage. Cancer Sci 2008;99:2142-51.
13. Nagai H, Ishihara T, Lee WH, Ohara H, Okazaki Y, Okawa K, et al. Asbestos surface provides a niche for oxidative modification. Cancer Sci 2011;102:2118-25.
14. Kubo Y, Takenaka H, Nagai H, Toyokuni S. Distinct affinity of nuclear proteins to the surface of chrysotile and crocidolite. J Clin Biochem Nutr 2012;51(3):221-6.
15. Jones JSP (ed.). Pathology of the mesothelium. Berlin Heiderberg: Springer-Verlag; 1987.
16. Donaldson K, Murphy FA, Duffin R, Poland CA. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010;7:5.
17. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553-66.
18. Toyokuni S. Iron and carcinogenesis: from Fenton reaction to target genes. Redox Rep 2002;7(4):189-97.
19. Okada S, Hamazaki S, Toyokuni S, Midorikawa O. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. Br J Cancer 1989;60:708-11.
20. Nagai H, Toyokuni S. Biopersistent fiber-induced inflammation and carcinogenesis: lessons learned from asbestos toward safety of fibrous nanomaterials. Arch Biochem Biophys 2010;502(1):1-7.
21. MacCorkle RA, Slattery SD, Nash DR, Brinkley BR. Intracellular protein binding to asbestos induces aneuploidy in human lung fibroblasts. Cell Motil Cytoskeleton 2006;63(10): 646-57.
22. Nakamura E, Makishima A, Hagino K, Okabe K. Accumulation of radium in ferruginous protein bodies formed in lung tissue: association of resulting radiation hotspots with malignant mesothelioma and other malignancies. Proc Jpn Acad Ser B Phys Biol Sci 2009;85(7):229-39.
23. Wriggleworth JM, Baum H. The biochemical function of iron. In: Jacobs A, Worwood M (eds.). Iron in biochemistry and medicine, II. London: Academic Press; 1980. p. 29-86.
24. Jiang L, Akatsuka S, Nagai H, Chew SH, Ohara H, Okazaki Y, et al. Iron overload signature in chrysotile-induced malignant mesothelioma. J Pathol 2012;228:366-77.
25. Toyokuni S. Genotoxicity and carcinogenicity risk of carbon nanotubes. Adv Drug Deliv Rev 2013 (in press) doi:pii: S0169-409X(13)00149-X. 10.1016/j.addr.2013.05.011.
26. Nagai H, Okazaki Y, Chew SH, Misawa N, Miyata Y, Shinohara H, et al. Intraperitoneal administration of tangled multiwalled carbon nanotubes of 15 nm in diameter does not induce mesothelial carcinogenesis in rats. Pathol Int 2013 (in press) doi: 10.1093/carcin/bgt267.
27. Chew SH, Okazaki Y, Nagai H, Misawa N, Akatsuka S, Yamashita K, et al. Cancer-promoting role of adipocytes in asbestos-induced mesothelial carcinogenesis through dysregu-lated adipocytokine production. Carcinogenesis 2013 (in press).
28. Hu Q, Akatsuka S, Yamashita Y, Ohara H, Nagai H, Okazaki Y, et al. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest 2010;90: 360-73.
29. Toyokuni S, Sagripanti JL. Iron-mediated DNA damage: sensitive detection of DNA strand breakage catalyzed by iron. J Inorg Biochem 1992;47:241-8.
30. Toyokuni S, Sagripanti J-L. DNA single- and double-strand breaks produced by ferric nitrilotriacetate in relation to renal tubular carcinogenesis. Carcinogenesis 1993;14:223-7.
31. Sasaki K, Ikuta K, Tanaka H, Ohtake T, Torimoto Y, Fujiya M, et al. Improved quantification for non-transferrin-bound iron measurement using high-performance liquid chromatography by reducing iron contamination. Mol Med Rep 2011;4(5):913-8.
32. Ebina Y, Okada S, Hamazaki S, Ogino F, Li JL, Midorikawa O. Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum- nitrilotriacetate complexes in rats. J Natl Cancer Inst 1986;76:107-13.
33. Li JL, Okada S, Hamazaki S, Ebina Y, Midorikawa O. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res 1987;47:1867-9.
34. Toyokuni S, Okada S, Hamazaki S, Minamiyama Y, Yamada Y, Liang P, et al. Combined histochemical and biochemical analysis of sex hormone dependence of ferric nitrilotriacetate-induced renal lipid peroxidation in ddY mice. Cancer Res 1990;50: 5574-80.
35. Okada S, Minamiyama Y, Hamazaki S, Toyokuni S, Sotomatsu A. Glutathione cycle dependency of ferric nitrilotriacetate-induced lipid peroxidation in mouse proximal renal tubules. Arch Biochem Biophys 1993;301:138-42.
36. Okada S. Iron-induced tissue damage and cancer: the role of reactive oxygen free radicals. Pathol Int 1996;46:311-32.
37. Toyokuni S, Uchida K, Okamoto K, Hattori-Nakakuki Y, Hiai H, Stadtman ER. Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sci USA 1994;91:2616-20.
38. Toyokuni S, Luo XP, Tanaka T, Uchida K, Hiai H, Lehotay DC. Induction of a wide range of C2-12 aldehydes and C7-12 acyloins in the kidney of Wistar rats after treatment with a renal carcinogen, ferric nitrilotriacetate. Free Radic Biol Med 1997;22: 1019-27.
39. Toyokuni S, Mori T, Dizdaroglu M. DNA base modifications in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int J Cancer 1994;57:123-8.
40. Toyokuni S, Mori T, Hiai H, Dizdaroglu M. Treatment of Wistar rats with a renal carcinogen, ferric nitrilotriacetate, causes DNA-protein cross-linking between thymine and tyrosine in their renal chromatin. Int J Cancer 1995;62:309-13.
41. ′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal car-cinogenesis model. Lab Invest 1997;76:365-74.
42. Akatsuka S, Yamashita Y, Ohara H, Liu YT, Izumiya M, Abe K, et al. Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS ONE 2012;7(8):e43403.
43. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54: 5547-51.
44. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995;11:511-5.
45. Sekido Y. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol Int 2011;61(6):331-44.
46. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 2013;34(7):1413-9.
47. Weinberg RA. The biology of cancer. New York: Garland Science, Tailor & Francis Group, LLC; 2007.
48. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothe-lioma. Nature Genet 2011;43(10):1022-5.
49. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nature Genet 2011;43(7):668-72.
50. Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012; 103(5):868-74.
51. Toyokuni S. Mysterious link between iron overload and CDKN2A/2B. J Clin Biochem Nutr 2011;48(1):46-9.
52. Toyokuni S. Role of iron in carcinogenesis: Cancer as a ferro-toxic disease. Cancer Sci 2009;100(1):9-16.
53. Fuqua BK, Vulpe CD, Anderson GJ. Intestinal iron absorption. J Trace Elem Med Biol 2012;26(2-3):115-9.
54. Weinberg ED. The hazards of iron loading. Metallomics 2010; 2(11):732-40.
55. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007; 42(10):830-6.
56. Zacharski L, Chow B, Howes P, Shamayeva G, Baron J, Dalman R, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002.
57. Guariglia R, Martorelli MC, Villani O, Pietrantuono G, Mansueto G, D'Auria F, et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leukemia Res 2011;35(5):566-70.
58. Nagai H, Okazaki Y, Chew SH, Misawa N, Yasui H, Toyokuni S. Deferasirox induces mesenchymal-epithelial transition in cro-cidolite-induced mesothelial carcinogenesis in rats. Cancer Prev Res 2013;6(11):1222-30.
59. Nagai H, Okazaki Y, Chew S, Misawa N, Yamashita Y, Akatsuka S, et al. Diameter of multi-walled carbon nanotubes is a critical factor in mesothelial injury and subsequent carcino-genesis. Proc Natl Acad Sci USA 2011;108(49):E1330-8.
60. Tanaka T, Akatsuka S, Ozeki M, Shirase T, Hiai H, Toyokuni S. Redox regulation of annexin 2 and its implications for oxidative stess-induced renal carcinogenesis and metastasis. Oncogene 2004;23:3980-9.
61. Dutta KK, Zhong Y, Liu YT, Yamada T, Akatsuka S, Hu Q, et al. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci 2007;98(12):1845-52.